メタ情報
| meta description平均長 | 112.31 |
|---|
| OGPありページ数 | 13 |
|---|
| Twitterカードありページ数 | 13 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 20 |
|---|
| ページあたり内部リンク平均 | 17.77 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| PFM | 1 |
| site | 0.979417 |
| any | 0.825783 |
| user | 0.576128 |
| Personal | 0.526316 |
| cookies | 0.5 |
| Website | 0.421053 |
| cookie | 0.394737 |
| you | 0.392133 |
| our | 0.31731 |
| use | 0.285841 |
| purposes | 0.26886 |
| disorders | 0.263158 |
| off | 0.249655 |
| time | 0.249655 |
| review | 0.236842 |
| Cut | 0.236842 |
| applications | 0.236842 |
| recommended | 0.230451 |
| these | 0.230451 |
| date | 0.217669 |
| data | 0.214184 |
| months | 0.211247 |
| prior | 0.211247 |
| third | 0.211247 |
| collected | 0.210526 |
| will | 0.205576 |
| PFS | 0.192043 |
| monitoring | 0.192043 |
| during | 0.192043 |
| after | 0.192043 |
| explore | 0.192043 |
| Therapy | 0.192043 |
| Management | 0.192043 |
| Guide | 0.192043 |
| SUPPORT | 0.192043 |
| RESOURCES | 0.192043 |
| does | 0.192043 |
| websites | 0.192043 |
| com | 0.192043 |
| median | 0.184211 |
| conditions | 0.184211 |
| part | 0.184211 |
| when | 0.184211 |
| processing | 0.184211 |
| Google | 0.184211 |
| safety | 0.180531 |
| response | 0.172838 |
| following | 0.172838 |
| Patient | 0.165487 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| Characteristics | Product | 4.897394 | 276 |
| label | open | 4.66435 | 212 |
| Fabre | Pierre | 4.600812 | 180 |
| ROI | outside | 4.574674 | 221 |
| Cancer | Eur | 4.489893 | 260 |
| binimetinib | plus | 4.463791 | 312 |
| Phase | randomised | 4.379765 | 212 |
| BRAFTOVI | MEKTOVI | 4.364868 | 348 |
| melanoma | mutant | 4.241535 | 320 |
| per | vary | 4.185137 | 104 |
| vemurafenib | versus | 4.180787 | 208 |
| comply | regulation | 4.145491 | 104 |
| encorafenib | plus | 4.116791 | 312 |
| multicentre | open | 4.109784 | 160 |
| regulation | usage | 4.107287 | 104 |
| accessing | responsibility | 4.105845 | 104 |
| Healthcare | outside | 4.102894 | 208 |
| BRAF | mutant | 4.049388 | 268 |
| responsibility | take | 4.030777 | 104 |
| binimetinib | encorafenib | 4.02744 | 351 |
| Please | aware | 3.95571 | 104 |
| Product | Summaries | 3.947103 | 172 |
| must | refer | 3.852299 | 104 |
| Summaries | based | 3.822346 | 130 |
| You | must | 3.788613 | 104 |
| accessing | such | 3.774853 | 104 |
| Adverse | events | 3.761673 | 61 |
| Lancet | Oncol | 3.759197 | 104 |
| label | randomised | 3.743565 | 157 |
| Ascierto | Dummer | 3.710006 | 209 |
| Choice | SmPCs | 3.624449 | 52 |
| DOI | JCO | 3.624449 | 52 |
| Bottomley | Musoro | 3.624449 | 52 |
| Bottomley | Coens | 3.624449 | 52 |
| Coens | Interpreting | 3.624449 | 52 |
| minimally | scores | 3.624449 | 52 |
| importantly | minimally | 3.624449 | 52 |
| Festino | Trojaniello | 3.624449 | 52 |
| Festino | Vanella | 3.624449 | 52 |
| Expert | Rev | 3.624449 | 52 |
| Heinzerling | Pharmacol | 3.624449 | 52 |
| Elgentler | Heinzerling | 3.624449 | 52 |
| Elgentler | Fluck | 3.624449 | 52 |
| Fluck | Tolerability | 3.624449 | 52 |
| ESMO | Open | 3.624449 | 52 |
| Lebbe | Lorigan | 3.624449 | 52 |
| Europe | retrospective | 3.624449 | 52 |
| longitudinal | retrospective | 3.624449 | 52 |
| longitudinal | survey | 3.624449 | 52 |
| MELODY | survey | 3.624449 | 52 |